

# Nir Peled

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8959365/publications.pdf>

Version: 2024-02-01

35  
papers

15,508  
citations

567281

15  
h-index

434195

31  
g-index

35  
all docs

35  
docs citations

35  
times ranked

15163  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1823-1833.	27.0	7,847
2	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2078-2092.	27.0	4,701
3	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. <i>Journal of Clinical Oncology</i> , 2019, 37, 537-546.	1.6	1,144
4	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1505-1517.	1.6	710
5	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score $\geq$ 50%. <i>Journal of Clinical Oncology</i> , 2021, 39, 2339-2349.	1.6	468
6	BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1128-1137.	1.1	160
7	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 387-397.	10.7	119
8	Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 439-449.	7.0	64
9	KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. <i>Journal of Clinical Oncology</i> , 2019, 37, 9013-9013.	1.6	42
10	Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget). <i>Journal of Clinical Oncology</i> , 2018, 36, 9010-9010.	1.6	40
11	Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1250-1258.	3.8	34
12	Gender and lung cancer-SEER-based analysis. <i>Annals of Epidemiology</i> , 2020, 46, 14-19.	1.9	33
13	GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. <i>Lung Cancer</i> , 2020, 148, 48-54.	2.0	18
14	Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2020, 38, 9582-9582.	1.6	16
15	Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC. <i>Journal of Clinical Oncology</i> , 2018, 36, 9021-9021.	1.6	15
16	Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2020, 43, 67-74.	2.4	14
17	Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. <i>Translational Oncology</i> , 2021, 14, 101184.	3.7	13
18	Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa125.	0.7	12

#	ARTICLE	IF	CITATIONS
19	PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024. <i>Journal of Thoracic Oncology</i> , 2017, 12, S8-S9.	1.1	11
20	Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort. <i>Clinical Lung Cancer</i> , 2019, 20, 278-286.e1.	2.6	10
21	Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma. <i>Case Reports in Oncology</i> , 2019, 12, 29-32.	0.7	9
22	BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 603223.	2.8	9
23	Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents?. <i>Thoracic Cancer</i> , 2020, 11, 2331-2334.	1.9	5
24	Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117556.	0.6	4
25	Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e125-e131.	1.1	3
26	Is ALK Inhibitor a Contraindication for Subsequent IVF Pregnancy?. <i>Journal of Thoracic Oncology</i> , 2019, 14, e176-e178.	1.1	2
27	Retroperitoneal Pseudotumor Induced by Crizotinib Treatment for c-MET exon 14 Skip Mutation NCSLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, e172-e174.	1.1	1
28	Increased Incidence of Lung Cancer Among Patients With Superficial Transitional Cell Carcinoma: A Potential Risk Cohort for Lung Cancer Screening. <i>Clinical Lung Cancer</i> , 2019, 20, 429-434.	2.6	1
29	Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence. <i>International Journal of Cancer</i> , 2021, 148, 1183-1191.	5.1	1
30	ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9121-TPS9121.	1.6	1
31	Stereotactic Radiosurgery for Brain Metastases in Small Cell Lung Cancer: The Davidoff Cancer Center Experience. <i>Israel Medical Association Journal</i> , 2020, 22, 22-26.	0.1	1
32	Real-world outcomes and clinical characteristics of patients with brain metastases from EGFR mutated non-small cell lung cancer: Data from a large retrospective study (REFLECT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9086-9086.	1.6	0
33	Rare targetable drivers (RTD) in NSCLC: PD-L1 expression, tumor mutation burden (TMB), microsatellite instability (MSI) and outcomes with immune check-point inhibitors (ICPi).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9076-9076.	1.6	0
34	Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3046-3046.	1.6	0
35	Circulating Tumor DNA T790M Testing as a Predictor of Osimertinib Efficacy in Epidermal Growth Factor Receptor Mutant Non-small Cell Lung Cancer: A Single Center Experience. <i>Israel Medical Association Journal</i> , 2019, 21, 394-398.	0.1	0